Novotech, the leading Asia Pacific centred biotech CRO with extensive experience in vaccine trials, is convening an expert panel webinar with Endpoints News covering the evolving landscape in vaccine development. (Register here)

Novotech research data shows between 2017 and 2021, there were close to 1,400 industry-sponsored single-country vaccine-based clinical trials globally, with the Asia Pacific involved in over 45% of the trials. Mainland China, India, Japan, Australia and South Korea were the frequently involved locations in the region. 

During this period the top 3 regions including the US (369), EU7 (162) and APAC5 (541) together contributed over 1,000 vaccine trials with Asia-Pacific contributing more than 50% of the global share of trials.

Download our latest data report here: Vaccines – Asia Pacific Clinical Trial Landscape

Novotech offers biotechs a unique and unparalleled suite of early to late-phase CRO services across Europe and the US, with a focus on Asia Pacific where the company has built a reputation for delivering high-quality expedited clinical trials. 

The Endpoints webinar, Keeping pace with the evolving global landscape in vaccine development, will hear from a panel of life science experts on the latest advancements and innovative modalities paving the way in the global vaccine development space including:

•    The COVID-19 impact on drug development and the regulatory landscape including mRNA vaccines. 
•    Key factors contributing to Asia Pacific being recognised as the hub for vaccine development and opportunities for biotech’s to leverage. 
•    Key considerations for pre-clinical and clinical planning to accelerate vaccine development, supporting a robust global strategy.

Date/Time: March 09 11:00 am - 12:00 pm EST
Register here


Dr. Sushant Sahastrabuddhe, Associate Director General at the International Vaccine Institute (IVI), joined in July 2010, leading the clinical trials of IVI’s typhoid vaccine and process to achieve its licensure, the global clinical development of and licensure of SK bioscience’s COVID-19 vaccines and Phase 1 and 2 trials of Bharat Biotech’s Chikungunya vaccine. As a vaccine enthusiast with more than 17 years of experience in multiple countries across diverse projects, he continues to lead collaborative efforts with companies and partners in Korea, India and globally to get these vaccines through early- to late-stages of their clinical development. Dr. Sahastrabuddhe is also the Associate Editor for Vaccines for tropical diseases and associated with Yonsei University as Research Professor and with Universite Claude Bernanrd, Lyon France as Research Fellow. In 2021, Dr. Sahastrabuddhe was named an ‘Honorary Citizen of Seoul’ for his contributions to the joint efforts with Korean companies and international partners to develop vaccines against COVID-19 and other diseases.

An Infectious Diseases Physician and Microbiologist, Dr. Paul Griffin was appointed as the Director of Infectious Diseases at Mater Health Services in 2013 and continues an appointment as an Associate Professor of Medicine at the University of Queensland Medical School. Additionally, Dr. Griffin chairs the Advanced Training Committee in Infectious Diseases with the Royal Australasian College of Physicians, the committee that oversees the training of Infectious Diseases specialists in Australia.
Previously, Dr. Griffin was the Principal Investigator (PI) and Medical Director at Nucleus Network, a contract research organization specializing in infectious diseases trials, which included a PI role on in excess of 125 clinical trials predominantly in Infectious Diseases including novel vaccines and COVID-19 vaccines. With fellowships in Infectious Diseases from the Royal Australasian College of Physicians, in Clinical Microbiology from the Royal College of Pathologists of Australasia and from the Australasian College of Tropical Medicine, Dr. Griffin has an active interest in vaccine education and advocacy and has become a trusted media authority and spokesperson across the nation during the COVID-19 pandemic.

Babaji Yadav is a Senior Consultant with over eight years of academic experience in pre-clinical oncology drug development and eight years of industry experience in drug development. Babaji has a strong background in pharmaceutical sciences with a Ph.D. in Pharmacology and Toxicology from the University of Otago, New Zealand. Previously he has worked as a Research Project Manager to oversee IND-enabling toxicology studies for lead oncology drugs and, prior to joining Novotech, was a Clinical Project Manager for early-phase oncology trials. Babaji is a UK Registered Toxicologist and at Novotech he is focused on providing technical toxicology advice and product development strategies to facilitate the entry of client’s compounds into clinical trials. Babaji has experience in small molecules, combination products, and biologicals including vaccines, proteins, monoclonal antibodies, and advanced cell and gene therapies.

Jennifer Arellano is the Director of Clinical Services in the Philippines with over 25 years of technical and leadership experience in managing clinical trial operations for sponsors and CROs. With a Bachelor of Industrial Pharmacy from the University of the Philippines and a Pharmacist license, Jennifer’s research operations experience includes monitoring, auditing, project leadership, feasibility, study start-up, driving inspection readiness and hosting regulatory inspection, client engagement and business development, learning & development and organization SOP development/review. Jennifer has contributed to the transformation of the Philippine clinical research industry – bringing improvement to the local clinical research regulations and practices and is the founding President of a non-profit organization, the Philippine Clinical Research Professionals Inc, with more than 400 members from pharmaceutical and CROs and has, more recently, volunteered pro-bono services during the Covid-19 pandemic to provide trial management consultancy to the Philippine DOH-funded trials such as WHO Solidarity COVID-19 Treatment and Vaccine trials, Avigan COVID-19 treatment trial, and Philippine Heart Association funded cardiovascular outcome study.

Novotech has recently acquired EastHORN a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent. The acquisition is part of Novotech’s global expansion program in Europe and the US.

Novotech has been benchmarked as a top 10 CRO among the world’s leading CROs, is the recipient of the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence award and the Asia-Pacific Contract Research Organization Company of the Year Award, and has signed 45 Leading Site Partnership agreements over the last 3 years.

Media contact

About Novotech 

Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase. 

Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006. 

The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice. 

For more information or to speak to an expert team member visit 

Other relevant content